A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma

Gene Therapy

Volumn 11, Issue 6, 2004, Pages 552-559

  Kanerva, A ^a,b,c   Bauerschmitz, G J ^c   Yamamoto, M ^c   Lam, J T ^c   Alvarez, R D ^d   Siegal, G P ^e   Curiel, D T ^c   Hemminki, Akseli ^a,b,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e University of Alabama at Birmingham   (United States)

Author keywords

Adenovirus; Biological therapy; Ovarian neoplasms; Virus replication

Indexed keywords

ADENOVIRUS VECTOR; CYCLOOXYGENASE 2; INTEGRIN;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY ADENOCARCINOMA; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN MOTIF; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS INFECTIVITY; VIRUS REPLICATION; WILD TYPE;

ADENOCARCINOMA; ADENOVIRUSES, HUMAN; ANIMALS; CELL DEATH; CELL LINE, TUMOR; CYCLOOXYGENASE 2; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; MICE; MICE, SCID; MODELS, ANIMAL; OVARIAN NEOPLASMS; PROMOTER REGIONS (GENETICS); PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 1842529456     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302181     Document Type: Article

References (26)

1. Vorburger SA, Hunt KK. Adenoviral gene therapy. Oncologist 2002; 7: 46-59.
2. Hemminki A, Alvarez RD. Adenoviruses in oncology: A viable option? BioDrugs 2002; 16: 77-87.
3. Bauerschmitz GJ, Barker SD, Hemminki A. Adenoviral gene therapy for cancer: From vectors to targeted and replication competent agents (Review). Int J Oncol 2002; 21: 1161-1174.
4. Yamamoto M. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology 2003; 125: 1203-1218.
5. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002; 190: 279-286.
6. Huang Q et al. The plasticity of dendritic cell responses to pathogens and their components. Science 2001; 294: 870-875.
7. Hirschowitz E, Hidalgo G, Doherty D. Induction of cyclooxygenase-2 in non-small cell lung cancer cells by infection with ΔE1, ΔE3 recombinant adenovirus vectors. Gene Therapy 2002; 9: 81-84.
8. Steer SA et al. Regulation of cyclooxygenase-2 expression by macrophages in response to double-stranded RNA and viral infection. J Immunol 2003; 170: 1070-1076.
9. Yamamoto M et al. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Mol Ther 2001; 3: 385-394.
10. Casado E et al. Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. Clin Cancer Res 2001; 7: 2496-2504.
11. Barker SD et al. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy. J Gene Med 2002; 5: 300-310.
12. Douglas JT et al. Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res 2001; 61: 813-817.
13. Okegawa T et al. The mechanism of the growth-inhibitory effect of coxsackie and adenovirus. receptor (CAR) on human bladder cancer: A functional analysis of car protein structure. Cancer Res 2001; 61: 6592-6600.
14. Suzuki K et al. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001; 7: 120-126.
15. Bauerschmitz GJ et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 2002; 62: 1266-1270.
16. Lam JT et al. Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids. Cancer Gene Ther 2003; 10: 377-387.
17. Denkert C et al. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 2002; 160: 893-903.
18. Dmitriev I et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713.
19. Hemminki A et al. An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther 2001; 4: 223-231.
20. Kanerva A et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 2002; 5: 695-704.
21. Hemminki A et al. Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy. Hum Gene Ther 2002; 13: 1505-1514.
22. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-1677.
23. O'Connor RJ, Hearing P. The E4-6/7 protein functionally compensates for the loss of E1A expression in adenovirus infection. J Virol 2000; 74: 5819-5824.
24. Barker SD et al. An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites. Gynecol Oncol 2001; 82: 57-63.
25. Kanerva A et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor targeted oncolytic virus. Mol Ther 2003; 8: 449-458.
26. Kanerva A et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002; 8: 275-280.